v3.23.1
CONSOLIDATED STATEMENTS OF PROFIT AND LOSS AND OTHER COMPREHENSIVE LOSS - USD ($)
 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disclosure of disaggregation of revenue from contracts with customers [line items]    
Revenue $ 8,561
Cost of revenue 9,926  
Gross profit (loss) (1,365)  
Operating expenses:    
Sales and Marketing 26,616 13,818
Research & Development 397,109 433,743
General and Administrative 5,307,671 1,286,118
Total operating expenses 5,731,396 1,733,679
Operating loss (5,732,761) (1,733,679)
Other income (expense):    
Interest expense (15,468) (15,438)
Other income (expense) 290,466 (753)
Total other income (expense) 274,998 (16,191)
Loss before income taxes (5,457,763) (1,749,870)
Net loss (5,457,763) (1,749,870)
Net loss attributable to non-controlling interest (269) (41,043)
Net loss attributable to Virax (5,457,494) (1,708,827)
Other comprehensive (loss)    
Foreign currency adjustment (111) (965)
Comprehensive loss (5,457,652) (1,748,905)
Comprehensive income, attributable to non-controlling interests (269) (78,065)
Comprehensive loss attributable to Virax $ (5,457,383) $ (1,670,840)
Basic and diluted weighted average shares outstanding    
Ordinary shares 10,629,835 9,563,260
Diluted ordinary shares 10,629,835 9,563,260
Basic and diluted net loss per share    
Basic net loss per share $ (0.51) $ (0.18)
Diluted net loss per share $ (0.51) $ (0.18)

Source

PDF HTML 20-F Filing
ZIP XLS HTML XBRL